Agios Pharmaceuticals Inc. (NASDAQ:AGIO) has received an average recommendation of “Buy” from the twelve ratings firms that are presently covering the company. Five equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $62.63.

Several equities research analysts recently issued reports on AGIO shares. Zacks Investment Research downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 5th. Canaccord Genuity reaffirmed a “buy” rating and issued a $90.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, September 8th. Needham & Company LLC started coverage on Agios Pharmaceuticals in a research report on Monday, October 24th. They issued a “buy” rating and a $60.00 target price on the stock. Cowen and Company reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research report on Thursday, November 3rd. Finally, Goldman Sachs Group Inc. reaffirmed a “neutral” rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, August 10th.

In other Agios Pharmaceuticals news, insider Scott Biller sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $55.00, for a total value of $275,000.00. Following the completion of the sale, the insider now owns 48,270 shares in the company, valued at approximately $2,654,850. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 2,504 shares of the firm’s stock in a transaction that occurred on Thursday, October 27th. The stock was sold at an average price of $48.94, for a total value of $122,545.76. Following the completion of the sale, the director now owns 108,405 shares of the company’s stock, valued at approximately $5,305,340.70. The disclosure for this sale can be found here. 10.55% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the company. First Mercantile Trust Co. purchased a new stake in shares of Agios Pharmaceuticals during the third quarter worth approximately $137,000. BlackRock Inc. increased its stake in shares of Agios Pharmaceuticals by 373.3% in the first quarter. BlackRock Inc. now owns 3,602 shares of the biopharmaceutical company’s stock worth $145,000 after buying an additional 2,841 shares in the last quarter. Teacher Retirement System of Texas increased its stake in shares of Agios Pharmaceuticals by 40.8% in the second quarter. Teacher Retirement System of Texas now owns 3,921 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 1,136 shares in the last quarter. Beech Hill Advisors Inc. purchased a new stake in shares of Agios Pharmaceuticals during the third quarter worth approximately $217,000. Finally, Parametrica Management Ltd purchased a new stake in shares of Agios Pharmaceuticals during the third quarter worth approximately $246,000. Institutional investors own 81.74% of the company’s stock.

Agios Pharmaceuticals (NASDAQ:AGIO) opened at 63.77 on Tuesday. The firm has a 50 day moving average price of $51.48 and a 200-day moving average price of $47.24. Agios Pharmaceuticals has a 12 month low of $33.50 and a 12 month high of $71.49. The firm’s market capitalization is $2.68 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.52) by $0.11. The business earned $8.98 million during the quarter, compared to analysts’ expectations of $7.82 million. Agios Pharmaceuticals had a negative return on equity of 53.39% and a negative net margin of 341.56%. The firm’s revenue was up 63.9% on a year-over-year basis. During the same period in the prior year, the company posted ($1.07) earnings per share. On average, equities analysts forecast that Agios Pharmaceuticals will post ($5.15) EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

5 Day Chart for NASDAQ:AGIO

Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.